Clinical Trials & Data Research has yielded encouraging results: SURMOUNT-1 Trial: All patients lost an average of 15-22.5% of their body weight over 72 weeks
doi:10.1001/jamaophthalmol.2025.2489 7.Hansen MS, Wlfel EM, Jeromdesella S, et al
The screening identified six key pharmacophoric features in the co-crystallized structure of PDE10A (PDB ID: 5UWF) and the ligand 16d, which included one hydrogen bond acceptors (HBA) interacting with Q726, an aromatic ring (AR) represented by the thiophene moiety, and four hydrophobic areas (HA) represented by phenol, sulfide, and fluorine groups
Also, those who are pregnant or nursing, planning to become pregnant, have a personal or family history of certain cancers, or have experienced angioedema, should not take GLP-1 agonists
These findings suggest that it may be beneficial for women to stay on a lower dose for a bit longer, allowing the body time to adjust to minimize side effects
We source our products through verified synthesis pipelines and subject every batch to independent, third-party laboratory verification
